Zolgensma is an AAV-9 based, one-time only gene therapy which supplements the survival of motor neuron 1 (SMN1) protein in patients with spinal muscular atrophy (SMA), which is functionally lacking in these patients. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.